• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Aridis Pharmaceuticals Announces $2 Million Offering

    8/2/23 8:17:00 AM ET
    $ARDS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARDS alert in real time by email

    Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced the pricing of an offering of 10,000,000 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 10,000,000 shares of common stock at a combined offering price of $0.20 per share of common stock (or pre-funded warrant) and accompanying warrant. Each warrant will have an exercise price per share of $0.20, will be exercisable immediately and will terminate on the five year anniversary of the date of issuance. The closing of the offering is expected to occur on or about August 4, 2023, subject to the satisfaction of customary closing conditions. 

    H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. 

    The gross proceeds to the Company from the offering are expected to be $2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. Aridis Pharmaceuticals currently intends to use the net proceeds from the offering for working capital and general corporate purposes. 

    The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-272128) originally filed with the Securities and Exchange Commission ("SEC") on May 22, 2023 and declared effective on August 1, 2023. The offering is being made only by means of a prospectus, which is part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC's website at http://www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at [email protected]. 

    The Company also has agreed that certain existing warrants to purchase up to an aggregate of (i) 2,473,778 shares of the Company's common stock that were previously issued in August 2021, as amended, at an exercise price of $2.00 per share and (ii) 7,207,208 shares of the Company's common stock that were previously issued in October 2022, at an exercise price of $1.11 per share, will be amended effective upon the closing of the offering, such that the amended warrants will have a reduced exercise price of $0.20 per share and a termination date on the five year anniversary of the closing date of the offering. 

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. 

    About Aridis Pharmaceuticals, Inc. 

    Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as first-line treatments to combat antimicrobial resistance (AMR) and viral pandemics. The Company is utilizing its proprietary ʎPEX™ and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture mAbs for therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized by the natural human immune system for high potency. Hence, they are already fit-for-purpose anddo not require further engineering optimization to achieve full functionality.

    The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antibacterial and antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care, which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. The Company's pipeline is highlighted below:

    Aridis' Pipeline

    AR-301 (VAP/HAP/CAP). AR-301 is a fully human IgG1 mAb currently in Phase 3 clinical development targeting gram-positive S. aureus alpha-toxin in ventilator associated pneumonia (VAP), ventilated hospital acquired pneumonia (HAP), and ventilated community acquired pneumonia (CAP) patients.

    AR-501 (cystic fibrosis). AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in cystic fibrosis patients. This program is currently in a Phase 2a clinical study in CF patients.

    AR-320 (VAP). AR-320 is a fully human mAb targeting S. aureus alpha-toxin for prevention of VAP. Statistically significant Phase 2 data in the target population of those ≤ 65 years of age was published in the September 2021 Lancet Infectious Diseases journal. The Company has completed discussions with the EMA and FDA on study design and recently launched the Phase 3 study.

    AR-701 (COVID-19). AR-701 is a cocktail of fully human mAbs discovered from convalescent COVID-19 patients that target multiple sites on the spike proteins of the SARS-CoV-2 virus.

    AR-101 (HAP). AR-101 is a fully human IgM mAb in Phase 2 clinical development targeting Pseudomonas aeruginosa liposaccharides serotype O11, which accounts for approximately 22% of all P. aeruginosa HAP cases worldwide. This program is licensed to the Serum Institute of India and Shenzhen Arimab.

    AR-201 (RSV infection). AR-201 is a fully human IgG1 mAb directed against the F-protein of diverse clinical isolates of respiratory syncytial virus (RSV). This program is licensed exclusively to the Serum Institute of India.

    AR-401 (blood stream infections). AR-401 is a fully human mAb preclinical program aimed at treating infections caused by gram-negative Acinetobacter baumannii.

    For additional information on Aridis Pharmaceuticals, please visit https://aridispharma.com/.

    Forward-Looking Statements

    Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Aridis' expectations, strategy, plans or intentions and include, without limitation, statements relating to closing of the offering, the satisfaction of closing conditions in the offering, and the use of net proceeds in the offering. These forward-looking statements are based on Aridis' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the need for additional financing, the timing of regulatory submissions, Aridis' ability to obtain and maintain regulatory approval of its existing product candidates and any other product candidates it may develop, approvals for clinical trials may be delayed or withheld by regulatory agencies, risks relating to the timing and costs of clinical trials, risks associated with obtaining funding from third parties, management and employee operations and execution risks, loss of key personnel, competition, risks related to market acceptance of products, intellectual property risks, risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses, risks associated with the uncertainty of future financial results, Aridis' ability to attract collaborators and partners and risks associated with Aridis' reliance on third party organizations. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Aridis' 10-K for the year ended December 31, 2022, and Aridis' other filings made with the Securities and Exchange Commission. Forward-looking statements included herein are made as of the date hereof, and Aridis does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

    Contact:

    Investor Relations

    Dave Gentry, CEO

    RedChip Companies

    [email protected]

    SOURCE Aridis Pharmaceuticals, Inc.



    Primary Logo

    Get the next $ARDS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARDS

    DatePrice TargetRatingAnalyst
    7/20/2021$11.00 → $19.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ARDS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aridis Provides Corporate Update

      LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC:ARDS) ("Aridis" or the "Company"), a biopharmaceutical company, today announced a corporate update on recent developments. Company update: The Company continues to diligently explore multiple paths to monetize its assets amidst a protracted challenging capital market and limited internal resources. During the second half of this year it has been in discussions with other pharmaceutical companies and investment firms on possible partnerships and investments in the clinical product candidates AR-301, AR-320, AR-501, and the APEX platform technology. The Company has substantially reduced its operational

      12/20/24 8:00:00 AM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aridis Provides Corporate Update

      LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC:ARDS) ("Aridis" or the "Company"), a biopharmaceutical company, today announced a corporate update on recent developments. The Company has been in sustained discussions with other pharmaceutical companies and investment firms on possible partnerships and investments on its clinical product candidates AR- 301, AR-320, AR-501, and the APEX platform technology. The principal goal for the discussions has been to build shareholder value by out-licensing or attracting capital investments to complete the final stages of product development. A summary of the status of the major programs is further highlight

      6/24/24 5:58:04 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update

      Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTCQB:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023. Third Quarter Highlights Received a grant award from the National Institute of Allergy and Infectious Diseases (NIAID) division of the National Institutes of Health (NIH), in collaboration with researchers at

      11/3/23 4:15:00 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hamilton John F

      4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)

      6/28/24 8:36:10 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Windham-Bannister Susan Richards

      4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)

      6/28/24 8:36:12 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Jafri Hasan

      4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)

      6/28/24 7:46:52 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDS
    Financials

    Live finance-specific insights

    See more
    • Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Reviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Rel

      9/22/23 1:30:00 PM ET
      $ARDS
      $RVPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report® on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 15, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (OTC:ARDS), Genetic Technologies Limited ((ASX:GTG, NASDAQ:GENE), and American Resources Corporation (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 16, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessAmerican Resources: https://www.redchip.com/assets/access/arec_accessAbout The

      9/15/23 9:00:00 AM ET
      $ARDS
      $AREC
      $GENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Coal Mining
      Energy
    • Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

      ORLANDO, FL / ACCESSWIRE / June 30, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) and Rail Vision Ltd. (NASDAQ:RVSN) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 1, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Aridis Pharmaceuticals (NASDAQ:ARDS): https://www.aridispharmainfo.com/interview_accessRail Vision (NASDAQ:RVSN): https://www.rvsninfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' expe

      6/30/23 9:00:00 AM ET
      $ARDS
      $RVSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Railroads
      Industrials

    $ARDS
    SEC Filings

    See more
    • Aridis Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

      8-K - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)

      6/27/24 4:15:22 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aridis Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)

      1/16/24 6:05:19 AM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Aridis Pharmaceuticals Inc.

      DEFA14A - Aridis Pharmaceuticals, Inc. (0001614067) (Filer)

      12/18/23 9:43:08 AM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc.

      SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)

      11/14/24 4:46:40 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)

      2/14/24 2:21:52 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Aridis Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Aridis Pharmaceuticals, Inc. (0001614067) (Subject)

      2/13/24 8:02:49 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Aridis Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Aridis Pharmaceuticals with a rating of Buy and set a new price target of $19.00 from $11.00 previously

      7/20/21 6:08:15 AM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Northland Securities resumed coverage on Aridis Pharmaceuticals with a new price target

      Northland Securities resumed coverage of Aridis Pharmaceuticals with a rating of Buy and set a new price target of $22.00

      2/24/21 4:13:46 AM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital resumed coverage on Aridis Pharmaceuticals with a new price target

      Roth Capital resumed coverage of Aridis Pharmaceuticals with a rating of Buy and set a new price target of $18.00

      1/24/21 2:54:23 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patzer Eric bought $50,000 worth of Common stock purchase (714,286 units at $0.07), increasing direct ownership by 419% to 884,600 units (SEC Form 4)

      4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)

      6/28/24 7:32:40 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Truong Vu bought $50,000 worth of Common stock purchase (714,286 units at $0.07), increasing direct ownership by 108% to 1,378,639 units (SEC Form 4)

      4 - Aridis Pharmaceuticals, Inc. (0001614067) (Issuer)

      6/28/24 7:29:41 PM ET
      $ARDS
      Biotechnology: Pharmaceutical Preparations
      Health Care